Estimation of insulin-like growth factor binding protein -1 in premature heart contraction patients

This study was conducted to provide an approach for the diagnosis and prognosis of atrial and ventricular presystole, with a particular focus on insulin-like growth factor-binding protein (IGF-1). The research was conducted in Najaf Governorate, Iraq, from July 1, 2024, to December 1, 2025, with monthly patient follow-ups. A total of 90 participants were enrolled, including 60 patients diagnosed with PVS and 30 healthy individuals as controls. The results were stratified into subgroups according to age, PVS type (atrial or ventricular), diagnosis status (newly diagnosed or under treatment), disease duration, blood pressure status, and body mass index (BMI) category. The results revealed a significant increase in IGF-1 levels among patients compared to the control group. Male patients showed significantly higher levels than female patients. Elderly patients (60-69 years old) showed a significantly higher incidence of ventricular fibrillation compared to other age groups. Additionally, newly diagnosed patients had a significantly higher incidence of ventricular fibrillation compared to treated patients. Hypertensive patients showed a significantly higher incidence of ventricular fibrillation compared to normotensive individuals. Regarding disease duration, those aged 1 week to 1 month showed significantly higher values compared to patients aged 1-5 years and older than 5 years. Patients with obesity had a significantly higher incidence rate compared to the control groups. In conclusion, the study suggests that insulin-like growth factor-1 (IGF-1) binding protein is a novel biomarker for atrial and ventricular fibrillation. It may serve as a valuable diagnostic and prognostic tool, potentially helping to reduce future complications associated with this condition.